Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 133, pseudogene (RNU6-133P) is a processed pseudogene derived from the gene encoding U6 small nuclear RNA, an essential non-coding RNA involved in the splicing of pre-messenger RNA in eukaryotes[3][1][5]. U6 snRNA is a core component of the spliceosome, where it has a highly conserved catalytic role in intron removal from mRNA precursors[3][1]. However, RNU6-133P specifically refers to a **pseudogene** version; pseudogenes are genomic DNA sequences similar to normal genes but typically nonfunctional and do not encode proteins[4][5][2]. RNU6-133P does not have a known biological function, disease association, or targeting drugs because, as a pseudogene, it is not expressed as a functional RNA or protein product[4][5]. Its main importance is as a marker of retrotranspositional activity in the genome, reflecting the evolutionary history of U6 snRNA gene copies in humans and other vertebrates[5]. There is no evidence that RNU6-133P is a therapeutic or diagnostic target, nor is it associated with known safety or off-target concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 133, pseudogene (RNU6-133P).